SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Next Generation Sequencing Assay for Detection of Circulating HPV DNA (cHPV-DNA) in Patients Undergoing Radical (Chemo)Radiotherapy in Anal Squamous Cell Carcinoma (ASCC).

Lee, JY; Cutts, RJ; White, I; Augustin, Y; Garcia-Murillas, I; Fenwick, K; Matthews, N; Turner, NC; Harrington, K; Gilbert, DC; et al. Lee, JY; Cutts, RJ; White, I; Augustin, Y; Garcia-Murillas, I; Fenwick, K; Matthews, N; Turner, NC; Harrington, K; Gilbert, DC; Bhide, S (2020) Next Generation Sequencing Assay for Detection of Circulating HPV DNA (cHPV-DNA) in Patients Undergoing Radical (Chemo)Radiotherapy in Anal Squamous Cell Carcinoma (ASCC). Front Oncol, 10. p. 505. ISSN 2234-943X https://doi.org/10.3389/fonc.2020.00505
SGUL Authors: Augustin, Yolanda Sydney

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (300kB) | Preview

Abstract

Background: Following chemo-radiotherapy (CRT) for human papilloma virus positive (HPV+) anal squamous cell carcinoma (ASCC), detection of residual/recurrent disease is challenging. Patients frequently undergo unnecessary repeated biopsies for abnormal MRI/clinical findings. In a pilot study we assessed the role of circulating HPV-DNA in identifying "true" residual disease. Methods: We prospectively collected plasma samples at baseline (n = 21) and 12 weeks post-CRT (n = 17). Circulating HPV-DNA (cHPV DNA) was measured using a novel next generation sequencing (NGS) assay, panHPV-detect, comprising of two primer pools covering distinct regions of eight high-risk HPV genomes (16, 18, 31, 33, 35, 45, 52, and 58) to detect circulating HPV-DNA (cHPV DNA). cHPV-DNA levels post-CRT were correlated to disease response. Results: In pre-CRT samples, panHPV-detect demonstrated 100% sensitivity and specificity for HPV associated ASCC. PanHPV-detect was able to demonstrate cHPV-DNA in 100% (9/9) patients with T1/T2N0 cancers. cHPV-DNA was detectable 12 weeks post CRT in just 2/17 patients, both of whom relapsed. 1/16 patients who had a clinical complete response (CR) at 3 months post-CRT but relapsed at 9 months and 1/1 patient with a partial response (PR). PanHPV-detect demonstrated 100% sensitivity and specificity in predicting response to CRT. Conclusion: We demonstrate that panHPV-detect, an NSG assay is a highly sensitive and specific test for the identification of cHPV-DNA in plasma at diagnosis. cHPV-DNA post-treatment may predict clinical response to CRT.

Item Type: Article
Additional Information: Copyright © 2020 Lee, Cutts, White, Augustin, Garcia-Murillas, Fenwick, Matthews, Turner, Harrington, Gilbert and Bhide. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Keywords: Plasma HPV-DNA, anal cancer, chemo-radiation, locally advanced, response prediction
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Front Oncol
ISSN: 2234-943X
Language: eng
Dates:
DateEvent
17 April 2020Published
20 March 2020Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
C46/A10588Cancer Research UKhttp://dx.doi.org/10.13039/501100000289
C7224/A13407Cancer Research UKhttp://dx.doi.org/10.13039/501100000289
PubMed ID: 32363162
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/111935
Publisher's version: https://doi.org/10.3389/fonc.2020.00505

Actions (login required)

Edit Item Edit Item